Monday, December 12, 2016

BRIEF-Interim results from phase 1b/2 study evaluating the combination of Merck's Keytruda and Eisai's Halaven injection presented at 2016 SABCS

* Interim results from phase 1b/2 study evaluating the

combination of Merck's Keytruda (pembrolizumab) and Eisai's

Halaven (eribulin mesylate) injection in metastatic

triple-negative breast cancer presented at 2016 SABCS

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)